Document is current
Any future updates will be listed below
-
Authors
Kumar, Kiven
Ooi, Justin SG https://orcid.org/0000-0003-4899-8255
Leong, Charlene H. M.
Tan, Hwee Cheng
Ng, Wy Ching https://orcid.org/0000-0001-5622-7691
Chan, Kuan Rong https://orcid.org/0000-0002-2427-671X
Finol, Esteban https://orcid.org/0000-0002-9830-439X
Ooi, Eng Eong https://orcid.org/0000-0002-0520-1544
-
Funding
Funding for this research was provided by:
National Medical Research Council (MOH-001271-00)
National Research Foundation Singapore (NRF-CRP27-2021RS-0001)
- License Information
-
More Information
Article History
Received: 30 March 2026
Accepted: 1 September 2026
First Online: 10 September 2026
Declarations
Competing interests: E.E.O. has served in advisory capacities on dengue for Sanofi Pasteur, Takeda Pharmaceuticals, MSD (Merck), Johnson & Johnson, and Novartis on dengue vaccines and therapeutics.
